Lombard Odier Asset Management (Switzerland)’s Iovance Biotherapeutics IOVA Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-530,452	Closed	-$3.24M	–	264
2023 Q1	$3.24M	Buy	530,452 +202,526	+62%	+$1.4M	0.28%	84
2022 Q4	$2.1M	Hold	327,926	–	–	0.17%	118
2022 Q3	$3.14M	Sell	327,926 -84,162	-20%	-$971K	0.27%	88
2022 Q2	$4.55M	Sell	412,088 -174	-0%	-$2.28K	0.39%	65
2022 Q1	$6.86M	Sell	412,262 -537,622	-57%	-$8.31M	0.54%	54
2021 Q4	$18.1M	Buy	949,884 +80,344	+9%	+$1.77M	1.16%	34
2021 Q3	$21.4M	Buy	869,540 +80,978	+10%	+$1.91M	1.33%	34
2021 Q2	$20.5M	Buy	788,562 +546,666	+226%	+$14.2M	1.04%	42
2021 Q1	$7.66M	Buy	+241,896	New	+$10M	0.51%	65

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s IOVA Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 530,452 shares — an estimated $3.24M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in IOVA in Q1 2021 and held it in 9 quarters. The position peaked at $21.4M in Q3 2021. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

Lombard Odier Asset Management (Switzerland) reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Lombard Odier Asset Management (Switzerland) sold 530,452 Iovance Biotherapeutics shares in Q2 2023, an estimated $3.24M.
Lombard Odier Asset Management (Switzerland) first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 9 quarters.
Lombard Odier Asset Management (Switzerland)'s Iovance Biotherapeutics position peaked at $21.4M in Q3 2021.
219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.